Courtney Beers
Director/Board Member chez SANGAMO THERAPEUTICS, INC.
Fortune : 21 876 $ au 31/03/2024
Profil
Courtney Beers is currently the Director at Sangamo Therapeutics, Inc. and the Chief Scientific Officer at Tizona Therapeutics, Inc. He previously worked as the Head of Cancer Immunotherapy at Cascadian Therapeutics LLC.
He obtained a doctorate degree from the University of Washington.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2023 | 32 650 ( 0,02% ) | 21 876 $ | 31/03/2024 |
Postes actifs de Courtney Beers
| Sociétés | Poste | Début |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Director/Board Member | 15/12/2022 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
Anciens postes connus de Courtney Beers
| Sociétés | Poste | Fin |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | Corporate Officer/Principal | - |
Formation de Courtney Beers
| University of Washington | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
